Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novaccess Global Inc XSNX

Healthcare Biotechnology
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.


OTCPK:XSNX - Post by User

Novaccess Global Inc > PATIENCE
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(36)
•••
Comment by virgo85on Feb 05, 2018 2:30pm
121 Views
Post# 27505554

RE:PATIENCE

RE:PATIENCEWhat do you mean by anither big run and what was the share price?.. The only small run with millions of shares traded was only to .004c... The big run has to be above.40c..
LittleFunds wrote: I think a little extra patience is going to be needed with this play. The whole MJ industry has been falling as of late so you cant really expect much to come from here. Once the MJ sector starts to rebound and the USA gets there stuff together, we should start to see an increase in SP. According to there last NR, they have already begun the plans for a build out with one MJ company, so this movement within the company has definatly started. Also they have this direct marketing campaign directed towards another 1000 grows, which im sure will bring in a bunch more business. Once we start hearing about the new jobs coming in and the companies attached to them (provided they tell us these details) we should be ready for anouther big run.. Patience will be rewarded here..


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities